Literature DB >> 18309232

Aggregopathy in neurodegenerative diseases: mechanisms and therapeutic implication.

C P Dohm1, P Kermer, M Bähr.   

Abstract

Many neurodegenerative diseases such as Parkinson's, Alzheimer's, Huntington's and Lou Gehrig's disease are associated with the misfolding and aggregation of proteins. While the relevance of these aggregates for neuronal degeneration and their impact on cellular function is still a matter of debate, several experimental therapeutic approaches have been aimed at interfering with protein aggregation. In this review, we want to summarize the current understanding of aggregate formation and toxicity in neurodegenerative diseases with an emphasis on Parkinson's disease. Furthermore, we will discuss current treatment strategies in these diseases targeting aggregate formation and concurrent neuronal cell death in these diseases. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18309232     DOI: 10.1159/000119459

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  23 in total

1.  Activation of autophagy by rapamycin does not protect oligodendrocytes against protein aggregate formation and cell death induced by proteasomal inhibition.

Authors:  Monika Noack; Christiane Richter-Landsberg
Journal:  J Mol Neurosci       Date:  2014-07-29       Impact factor: 3.444

2.  Inhibition of HDAC6 modifies tau inclusion body formation and impairs autophagic clearance.

Authors:  Janina Leyk; Olaf Goldbaum; Monika Noack; Christiane Richter-Landsberg
Journal:  J Mol Neurosci       Date:  2014-12-02       Impact factor: 3.444

3.  Amyloid β-peptide 25-35 self-assembly and its inhibition: a model undecapeptide system to gain atomistic and secondary structure details of the Alzheimer's disease process and treatment.

Authors:  Marina Naldi; Jessica Fiori; Marco Pistolozzi; Alex F Drake; Carlo Bertucci; Rongliang Wu; Krzysztof Mlynarczyk; Slawomir Filipek; Angela De Simone; Vincenza Andrisano
Journal:  ACS Chem Neurosci       Date:  2012-09-04       Impact factor: 4.418

Review 4.  Role of the ubiquitin-proteasome system in nervous system function and disease: using C. elegans as a dissecting tool.

Authors:  Márcio S Baptista; Carlos B Duarte; Patrícia Maciel
Journal:  Cell Mol Life Sci       Date:  2012-03-03       Impact factor: 9.261

5.  Oxidative stress promotes uptake, accumulation, and oligomerization of extracellular α-synuclein in oligodendrocytes.

Authors:  Katharina Pukass; Christiane Richter-Landsberg
Journal:  J Mol Neurosci       Date:  2013-11-12       Impact factor: 3.444

6.  Potassium depolarization and raised calcium induces α-synuclein aggregates.

Authors:  Jordan Follett; Bonnie Darlow; Mathew B Wong; Jacob Goodwin; Dean L Pountney
Journal:  Neurotox Res       Date:  2012-12-19       Impact factor: 3.911

7.  Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies.

Authors:  Selvaraju Veeriah; Barry S Taylor; Shasha Meng; Fang Fang; Emrullah Yilmaz; Igor Vivanco; Manickam Janakiraman; Nikolaus Schultz; Aphrothiti J Hanrahan; William Pao; Marc Ladanyi; Chris Sander; Adriana Heguy; Eric C Holland; Philip B Paty; Paul S Mischel; Linda Liau; Timothy F Cloughesy; Ingo K Mellinghoff; David B Solit; Timothy A Chan
Journal:  Nat Genet       Date:  2009-11-29       Impact factor: 38.330

Review 8.  The Pathogenic Role of Ganglioside Metabolism in Alzheimer's Disease-Cholinergic Neuron-Specific Gangliosides and Neurogenesis.

Authors:  Toshio Ariga
Journal:  Mol Neurobiol       Date:  2017-01       Impact factor: 5.590

9.  Increased generation of cyclopentenone prostaglandins after brain ischemia and their role in aggregation of ubiquitinated proteins in neurons.

Authors:  Hao Liu; Wenjin Li; Muzamil Ahmad; Marie E Rose; Tricia M Miller; Mei Yu; Jie Chen; Jordan L Pascoe; Samuel M Poloyac; Robert W Hickey; Steven H Graham
Journal:  Neurotox Res       Date:  2013-01-25       Impact factor: 3.911

Review 10.  Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding.

Authors:  Wendy Noble; Claire J Garwood; Diane P Hanger
Journal:  Prion       Date:  2009-04-21       Impact factor: 3.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.